Guillain-Barré Syndrome Presentation

9,562 views

Published on

Conditions in OT
Prof. S. St. Louis.
Dominican University of California

Published in: Education, Health & Medicine
0 Comments
6 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
9,562
On SlideShare
0
From Embeds
0
Number of Embeds
21
Actions
Shares
0
Downloads
565
Comments
0
Likes
6
Embeds 0
No embeds

No notes for slide

Guillain-Barré Syndrome Presentation

  1. 1. GUILLAIN-BARRÉ SYNDROME Linda Roybal & Sarah Jane Calub
  2. 2. DESCRIPTIONAcute autoimmune disease marked by inflammation of theperipheral nerves, affecting arms and legsInvolves destruction of the myelin sheath surroundinglargest, most myelinated sensory and motor fibers, resultingin disrupted proprioception and weakness.
  3. 3. ETIOLOGYNo clear causeNeither contagious nor hereditaryInappropriate immune responsePossible vaccine causal link
  4. 4. INCIDENCE &PREVALENCEGBS affects 2 per 100,000 annually (1,500 people/year)Nondiscriminatory: can affect persons of any gender, age, orethnic background
  5. 5. SIGNS AND SYMPTOMSNumbness and tingling in hands and feetDistal progression: muscle weakness, diminished reflexesand proprioception, decreased sensationFor some, progresses to trunk, face, and cranial nerves,resulting in difficulty swallowing, chewing, speaking, andfacial expressionsDeep, aching pain/hypersensitivity to touchRespiratory/cardiac dysfunction and failure
  6. 6. COURSE/PROGNOSIS80% experience complete recoveryRecovery may last from 2 months to 2 years3 distinct phases: Acute (4 wks) - initial rapid onset of symptoms Plateu (few days to few weeks) - symptoms neither worsen nor improve Recovery - gradual improvement
  7. 7. DIAGNOSIS Diagnostic testing for GBS includes Physical and neurological exam Lumbar puncture Computed Tomography (CT) scan
  8. 8. MEDICAL/SURGICALMANAGEMENTIntravenous immunoglobin therapy: prevents immunesystem from further attacking Schwann cells and myelin byblocking receptors on microphagesPlasmapheresis: filters blood plasma to removeantibodies and aids in replacing lost fluidsCorticosteroids: inhibit inflammation associated w/symptoms
  9. 9. IMPACT ON CLIENTLimited physical mobilityInability to engage in meaningful occupations because ofpain, extreme muscle weakness in arms and legs, and fatigueSensory functions impairedUsing cultural contexts to structure intervention activities
  10. 10. REFERENCESGuillain-Barré Syndrome Support Group (2009) A Quick Guide to Guillain-Barré Syndrome and CIDP. Guillain-Barré Support Group, Sleaford.Little evidence that supports a causal link between most vaccines and Guillain-Barre syndrome. (2009). Drugs & Therapy Perspectives, 25(11), 21-23.Lugg, J. (2010). Recognising and managing Guillain-Barre syndrome. Emergency Nurse, 18(3), 27-30.Lundy-Ekman, L. (2007). Neuroscience: fundamentals for rehabilitation (3rd ed.). St. Louis, Mo.: Saunders/Elsevier.

×